(Q47281565)

13 January 2018

editorial

0 references

review article

1 reference

title

Hirudin versus heparin and low-molecular-weight heparin: and the winner is... (English)

1 reference

13 January 2018

1 reference

1 reference

Hull RD

1

1 reference

13 January 2018

Pineo GF

series ordinal

2

1 reference

13 January 2018

Raskob GE

series ordinal

3

1 reference

13 January 2018

publication date

1 September 1998

1 reference

13 January 2018

published in

Translational Research

1 reference

13 January 2018

volume

132

1 reference

13 January 2018

issue

3

1 reference

13 January 2018

page(s)

171-174

1 reference

13 January 2018

The development of hirudin as an antithrombotic drug

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

Hirudin-based synthetic peptides as inhibitors of thrombin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

Hirudin: clinical potential of a thrombin inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

Hirudin causes more bleeding than heparin in a rabbit ear bleeding model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

Anticoagulation in patients with heparin-induced thrombocytopenia type II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990164-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-2143(98)90164-0

1 reference

13 January 2018

1 reference

13 January 2018